Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR) — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR) — Stella

Recruiting

Back to NSCLC, Stage I trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin Municipality

Key details

Phase

Safety & dosing

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Enrollment target

~65 participants

Started

October 2022

Primary completion

October 2024

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years and older

Last updated January 2023

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov